4 active trials 2 recruiting 1 Phase 3 9 disease areas
| Phase 1 | 1 | |
| Phase 1/2 | 1 | |
| Phase 2 | 1 | |
| Phase 2/3 | 1 |
| NCT ID | Title | Condition | Status | Updated |
|---|---|---|---|---|
| Phase 2/3 | ||||
| NCT06295731 | INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC | Head and Neck Squamous Cell Carcinoma (HNSCC) | Active, Not Recruiting | 2026-05-08 |
| Phase 2 | ||||
| NCT04950075 | Study of INBRX-109 in Conventional Chondrosarcoma | Conventional Chondrosarcoma | Active, Not Recruiting | 2026-07-14 |
| Phase 1/2 | ||||
| NCT04198766 | Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in… | Solid Tumor | Recruiting | 2026-07-29 |
| Phase 1 | ||||
| NCT03715933 | Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors… | Ewing Sarcoma | Recruiting | 2026-09-08 |
Head & Neck Cancer (2) · Sarcoma (2) · Bladder Cancer (1) · Colorectal Cancer (1) · Gastric Cancer (1) · Kidney Cancer (1) · Lung Cancer (1) · Melanoma (1) · Non-Small Cell Lung Cancer (NSCLC) (1)